Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
SystImmune and Bristol Myers Squibb reported positive Phase 3 PANKU-Lung01 interim results for iza-bren in previously-treated EGFR-mutated NSCLC, with median PFS of 11.1 months versus 5.7 months for platinum-based chemotherapy (HR 0.40, p<0.0001). Response rates also favored iza-bren (60.2% vs 34.5% cORR) with a manageable safety profile, and the data were presented at ESMO 2026 and published in The Lancet.
Key figures
- Drug Name
- izalontamab brengitecan (iza-bren, BL-B01D1)
- Phase Of Trial
- Phase 3
- Ci 95
- 0.31-0.51
- P value
- <0.0001
- Corr control
- 34.5%
- Hazard ratio
- 0.40
- Corr iza bren
- 60.2%
- Adjudicated ild
- 0.9%
- Mdor control months
- 5.7
- Mdor iza bren months
- 10.4
- Median follow up months
- 14.6
- Median pfs control months
- 5.7
- Trae discontinuation rate
- 1.9%
- Median pfs iza bren months
- 11.1
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.